Perindopril Erbumine has 17 known drug interactions based on U.S. FDA drug labeling data. 12 are classified as major interactions requiring close medical supervision. Notable interactions include combinations with Amiloride, Cyclosporine, Diuretics. Patients taking Perindopril Erbumine should inform their healthcare provider of all current medications — including over-the-counter drugs and supplements — to avoid potentially harmful combinations. Data sourced from OpenFDA and the NIH National Library of Medicine.
- Total
- 17
- Major
- 12
- Moderate
- 1
- Minor
- 1
Major (12)
- Perindopril Erbumine + Amiloride— Risk of hyperkalemia. Perindopril may increase serum potassium by decreasing aldosterone production.
- Perindopril Erbumine + Cyclosporine— Risk of hyperkalemia. Cyclosporine is capable of increasing serum potassium.
- Perindopril Erbumine + Diuretics— Excessive drop in blood pressure, especially in patients recently started on diuretics. Bioavailability of perindoprilat…
- Perindopril Erbumine + Heparin— Risk of hyperkalemia. Heparin is capable of increasing serum potassium.
- Perindopril Erbumine + Indomethacin— Risk of hyperkalemia due to drug's potential to increase serum potassium. May also increase risk of renal impairment.
- Perindopril Erbumine + Lithium— Increased serum lithium levels and symptoms of lithium toxicity reported. Frequent monitoring of serum lithium concentra…
- Perindopril Erbumine + Mao Inhibitors— Increased risk of angioedema with dual inhibition of renin-angiotensin system.
- Perindopril Erbumine + Nsaids— May lead to increased risk of renal impairment and loss of antihypertensive effect.
- Perindopril Erbumine + Potassium Supplements— Risk of hyperkalemia. Perindopril may increase serum potassium by decreasing aldosterone production.
- Perindopril Erbumine + Sodium Aurothiomalate— Nitritoid reactions reported rarely, including facial flushing, nausea, vomiting, and hypotension.
- Perindopril Erbumine + Spironolactone— Risk of hyperkalemia. Perindopril may increase serum potassium by decreasing aldosterone production.
- Perindopril Erbumine + Triamterene— Risk of hyperkalemia. Perindopril may increase serum potassium by decreasing aldosterone production.
Moderate (1)
- Perindopril Erbumine + Rapamycin— 7.9 mTOR Inhibitors Patients taking concomitant mTOR (mammalian target of rapamycin) inhibitor therapy may be at increas…
Minor (1)
- Perindopril Erbumine + Digoxin— Controlled pharmacokinetic study showed no effect on plasma digoxin concentrations, though effect of digoxin on perindop…